BPC-157 review weighs thin human evidence against UK regulatory limits
The piece surveys preclinical healing data for the pentadecapeptide and notes it holds no UK marketing authorisation for human use.
PR
By Priya Raman · Science Reporter
Sep 24 23:08 ETSource: nerdbot
The wire
- 01A review article summarises BPC-157 research and the UK regulatory position, where the peptide is sold for laboratory use rather than approved therapy.
- 02BPC-157 is among the most requested recovery peptides at clinics, so practitioners need a clear account of what evidence exists.
- 03Nearly all cited work is animal or in-vitro; no controlled human trials support the healing claims circulating in the gray market.
From the source
Read at nerdbot.comBPC-157 Research: Understanding the Science, Evidence, and UK Regulatory Landscape
